Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.
Yusuke HamakawaYoko AgemiAya ShibaToshiki IkedaYuko HigashiMasaharu AgaKazuhito MiyazakiYuri TaniguchiYuki MisumiYukiko NakamuraTsuneo ShimokawaYusuke SaigusaNobuaki KobayashiHiroaki OkamotoTakeshi KanekoPublished in: Cancer medicine (2023)
PD-L1 TPS ≥20% in patients with EGFR-mutated NSCLC may be associated with early resistance to osimertinib.